Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its second quarter net loss rose year over year as it continues to advance its lung cancer liquid biopsy test, DetermaVu.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of 5.4 million, or $.10 per share, compared to $4.5 million, or $.12 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any revenues for the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.